Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Palisade Bio, Inc. (PALI : NSDQ)

• Company Description    Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $0.60 Daily Weekly Monthly 20 Day Moving Average: 533,810 shares Shares Outstanding: 9.12 (millions) Market Capitalization: $5.45 (millions) Beta: 1.40 52 Week High: $4.32 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.63% -27.92% 12 Week -6.64% -15.19% Year To Date -63.76% -68.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7750 El Camino Real Suite 2A - Carlsbad,CA 92009 USA ph: 858-704-4900 fax: - pali@jtcir.com http://www.palisadebio.com

• General Corporate Information    Officers J.D. Finley - Chief Executive Officer; Chief Financial Officer; Donald A. Williams - Chairman Binxian Wei - Director Margery Fischbein - Director Robert J. Trenschel - Director Peer Information Palisade Bio, Inc. (CORR.) Palisade Bio, Inc. (RSPI) Palisade Bio, Inc. (CGXP) Palisade Bio, Inc. (BGEN) Palisade Bio, Inc. (GTBP) Palisade Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 696389402 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 9.12 Most Recent Split Date: 4.00 (0.07:1) Beta: 1.40 Market Capitalization: $5.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 82.53% vs. Previous Quarter: -23.40% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -214.94 03/31/25 - -178.96 12/31/24 - -169.34 ROA 06/30/25 - -135.09 03/31/25 - -127.35 12/31/24 - -126.26 Current Ratio 06/30/25 - 1.62 03/31/25 - 2.84 12/31/24 - 3.24 Quick Ratio 06/30/25 - 1.62 03/31/25 - 2.84 12/31/24 - 3.24 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.44 03/31/25 - 1.21 12/31/24 - 2.71 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©